Update shared on 11 Nov 2025
Fair value Decreased 10%Narrative Update on Definitive Healthcare: Analyst Price Target Revision
Analysts have lowered their price target for Definitive Healthcare from $4.54 to $4.06 per share, citing concerns about decelerating revenue growth and slightly reduced profit margins.
What's in the News
- The company has issued earnings guidance for the fourth quarter of 2025, projecting revenue between $59.0 million and $60.0 million (Key Developments).
- The company has raised its full year 2025 revenue guidance and now expects $239.0 million to $240.0 million, an increase of $2.0 million at the lower end of the previous range (Key Developments).
Valuation Changes
- Fair Value Estimate has decreased from $4.54 to $4.06 per share.
- Discount Rate has risen from 8.64% to 9.27%, which indicates increased perceived risk.
- Revenue Growth projection has declined further, from -0.22% to -1.16%.
- Net Profit Margin is down from 8.77% to 7.99%.
- Future P/E Ratio has decreased from 31.10x to 23.54x, suggesting a less optimistic earnings outlook.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.